A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies
Phase of Trial: Phase I/II
Latest Information Update: 30 Aug 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Isatuximab (Primary)
- Indications Glioblastoma; Head and neck cancer; Liver cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 10 May 2019 Planned End Date changed from 1 Jan 2023 to 1 Apr 2024.
- 10 May 2019 Planned primary completion date changed from 1 Jan 2023 to 1 Apr 2024.
- 27 Mar 2019 Planned End Date changed from 14 Sep 2022 to 1 Jan 2023.